Technetium-99m exametazime (HMPAO)

Approved Use: 

• As an adjunct in the detection of altered regional cerebral perfusion in stroke
• Leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease 

​Dose: 

• Cerebral scintigraphy: 10 - 20 mCi
• Tc-99m labeled leukocytes: 7 - 25 mCi

Brand Name: Ceretec™
Manufacturer: GE Healthcare

***2019 NEW STABILIZED PRODUCT*** 
Package Insert (stabilized kit)
Letter from Manufacturer November 2018 (new formulation)
***More info coming soon***

Package Insert (non-stabilized kit)
How Supplied: 5 vial kit
NDC#: 17156-022-05



OLD PRODUCT - DISCONTINUED MARCH 2019
Package Insert (stabilized kit)  
How Supplied:

• 5 vials Exametazime 0.5mg
• 5 vials Methylene Blue USP 1% (1cc)
• 5 vials 0.003 M Monobasic Sodium Phosphate USP and Dibasic Sodium Phosphate USP in 0.9% NaCl Injection USP (4.5cc)
• 15 syringe filters (0.45µm)

NDC#: 17156-023-05

​Leukocyte Labeling Instructions
​Brain Imaging Kit Prep
QC Worksheet
Labeling Efficiency Worksheet

Clinical Guidelines:

• ACR-SPR Practice Parameter for the Performance of SPECT Brain Perfusion and Brain Death Examinations (2016)
• ACR-SPR Practice Parameter for the Performance of Scintigraphy for Inflammation and Infection (2014)
• SNMMI Procedure Standard for Brain Death Scintigraphy 2.0 (2012)
• ​EANM Guidelines for Labeling of Leukocytes with Tc-99m HMPAO (2010)
• ​SNMMI Procedure Standard for Brain Perfusion SPECT Using Tc-99m Radiopharmaceuticals 3.0 (2009)
• SNMMI Procedure Standard for Tc-99m HMPAO-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation 3.0 (2004)